Rigoberto Gómez Gutiérrez

Rigoberto Gómez Gutiérrez

Auto-generated profile, based on publicly available information

Rigoberto Gómez Gutiérrez

Hematology Service, IDC Hematooncólogos S.A, Cali, Colombia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
CSClaudia Sossa-Melo
Claudia Sossa-Melo
VAVirginia Abello-Polo
Virginia Abello-Polo
LSLuis A. Salazar
Luis A. Salazar
APAngela M. Peña
Angela M. Peña
MLMaría Luna-González
María Luna-González
PMPau Montesinos
Pau Montesinos
There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60–98), 55% were men, 61% had an ECOG < 2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), Low-Intensity Regimen Based on Low-Dose Cytarabine (LDAC-based) (12.6%), hypomethylating agents (HMAs, with/without venetoclax) (35.3%), and supportive care (15.2%). The overall survival (OS) rate was 35.2% at 1 year and 5.6% at 5 years (13.7% for IC, 9.4% for LDAC-based, and 0% for other treatments); with median OS of 8.2 months (10.6 months after IC, 8.8 months after non-IC, 8.9 months after azacitidine/decitabine, 8.2 months after azacitidine-venetoclax, and 1.9 months with supportive care). Only 1.5% of patients underwent a transplant in the first line. The Leukemia-free survival (LFS) rate was 45.8% at 1-year and 13.7% at 5-years (22.4% for IC, 9.4% and 0% for other treatments); with median LFS of 9.5 months (17.3 months after IC, 7.4 months after LDAC-based, and 10.8 months after HMA). This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients.

30 June 2024 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
TPTomas Andrés Acosta Pérez
Tomas Andrés Acosta Pérez
MMMaría Alejandra Obando Martínez
María Alejandra Obando Martínez
RGRigoberto Gómez Gutiérrez
Rigoberto Gómez Gutiérrez
EOEmmanuel Orjuela
Emmanuel Orjuela
LTLizeth Acosta Tascón
Lizeth Acosta Tascón
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma in adults, with a growing increase in prevalence in some countries, but to date with little information from studies in the Colombian population. Objective: To describe the characteristics of a population of patients diagnosed with MF in a specialized reference center in the city of Cali, Colombia. Methods: Descriptive cross-sectional study that included patients older than 18 years of age of both sexes with a diagnosis of MF, defined by biopsy and analyzed by a complete team of pathologists, oncologists, dermatologists, treated in the outpatient and hospitalization services in the Hematoncologos , clinic based in Cali, between the years 2013 - 2023. Result: A total of 21 patients met all the criteria for entry into the study, 76% of them were women, the vast majority from the city of Cali 14 (66%), the median age was 66 years (23- 81), the average in months from the onset of symptoms to diagnosis was 23.2 months. The vast majority of patients were in early stages of the disease, the presentation in plaques was the most common (47.6%). Conclusions: In our study, a higher prevalence of the disease was observed in women, a particularly important fact because it is not the usual distribution worldwide, with an age of presentation similar to that of global studies. A very important fact in our study is that the diagnosis was established earlier compared to the global average.

20 February 2023 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
MRMaría Elena Pantoja Rosero
María Elena Pantoja Rosero
WMWilfredo Antonio Rivera Martínez
Wilfredo Antonio Rivera Martínez
RGRigoberto Gómez-Gutiérrez
Rigoberto Gómez-Gutiérrez
MSMaría Consuelo Santamaría
María Consuelo Santamaría
MHMiguel Ángel Mina Hinestroza
Miguel Ángel Mina Hinestroza
JPJose Darío Portillo-Miño
Jose Darío Portillo-Miño
Epithelioid hemangioendothelioma (EHE) is a malignant tumor possibly of vascular origin. Its usual location is the soft tissues, mediastinum, central nervous system, pleura, lungs, liver and bone. However, its appearance in the heart is extremely rare. We present the case of a 67-year-old male patient who consulted for progressive dyspnea, edema of the lower limbs and painful congestive hepatomegaly. Primary cardiac HEE is diagnosed by biopsy. Subsequently, tumor recurrence was documented, which is why the Tumor Board, which decided to start chemotherapy (Paclitaxel plus liposomal Doxorubicin for 6 cycles), evaluated him. The patient continues to be monitored by Oncology with evidence of stable disease. Primary cardiac HEE is a very rare tumor. Paclitaxel plus doxorubicin treatment is a chemotherapy regimen that may be considered in the management of advanced or recurrent primary cardiac HEE after cardiac surgery.

20 February 2023 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
OMOscar Felipe Borja Montes
Oscar Felipe Borja Montes
DSDaniela Marulanda Sandoval
Daniela Marulanda Sandoval
JZJose Leonel Zambrano
Jose Leonel Zambrano
RGRigoberto Gómez Gutiérrez
Rigoberto Gómez Gutiérrez
Mastocytosis are a group of diseases characterized by the pathological increase and accumulation of mast cells in one or several organs. They can be divided into variants of cutaneous mastocytosis CM, systemic mastocytosis SM and localized mast cell tumors. They are considered extremely rare diseases, also with limitations in their detection given the current lack of knowledge and the recent consensus of their diagnostic criteria. There is no clarity on therapeutic strategies. In Colombia there are few articles that report isolated cases. Objective: To identify the frequency, risk factors, clinical and paraclinical response to treatment of patients with mastocytosis in a reference center in the city of Cali, between June 2004 and June 2019. Method: A retrospective review was made of cases of mastocytosis that occurred in a period of 15 years in the reference center. Finding 7 patients until the period of June 2019. The diagnosis was made according to the existing WHO guidelines and was confirmed with a skin biopsy for patients with CM, and with a bone marrow biopsy for patients with SM. The serum tryptase level was estimated in all patients. Characterization of variables was carried out. Which were analyzed with Stata 13.0 siftware. Informed consent was obtained from each patient according to the guidelines of the local ethics committee. Results: 4 cases of CM and 3 cases of SM were identified. Conclusion: The findings of this series are comparable to those reported in the world literature.

31 May 2022 in Revista Colombiana de Gastroenterología
Verified
Journal Article
Open access
PDF file
JTJuan Manuel Hernández Torres
Juan Manuel Hernández Torres
GPGustavo Alexander López Paredes
Gustavo Alexander López Paredes
JMJosé Mauricio González Murrillo
José Mauricio González Murrillo
RGRigoberto Gómez Gutierrez
Rigoberto Gómez Gutierrez
JCJosé Mauricio Ocampo Chaparro
José Mauricio Ocampo Chaparro
La trombosis venosa de sitios inusuales como la esplácnica continúa siendo un reto no solo diagnóstico sino también terapéutico para el clínico debido a su forma de presentación y las patologías asociadas. La neoplasia mieloproliferativa latente JAK2 (cinasa de Janus 2) positiva asociada con síndrome de plaqueta pegajosa es inusual. Se presenta un caso clínico de una paciente de 38 años de edad que debutó con dolor abdominal de inicio súbito que sugirió un posible origen vascular. Se diagnosticó trombosis esplácnica en relación con neoplasia mieloproliferativa latente por la identificación de la mutación de la JAK2V617F y síndrome de plaqueta pegajosa mediante agregometría plaquetaria. Se administró de manera off-label anticoagulación con rivaroxabán 20 mg/día. Durante su seguimiento ambulatorio no ha presentado nuevos episodios trombóticos.

1 November 2022 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
AFAntonio José Paredes Fernández
Antonio José Paredes Fernández
MHMiguel Ángel Mina Hinestroza
Miguel Ángel Mina Hinestroza
MVMelissa Fernanda Lara Viáfara
Melissa Fernanda Lara Viáfara
VGValeria Andrea Gualtero García
Valeria Andrea Gualtero García
RCRodrigo Cárdenas-Perilla
Rodrigo Cárdenas-Perilla
RGRigoberto Gómez Gutiérrez
Rigoberto Gómez Gutiérrez
Kikuchi-Fujimoto disease (KFD) is a great mimic. Its clinical presentation resembles infectious entities, as well as reumatological diseases, lymphoproliferative disorders, or metastatic lesions. It is a benign, rare, self-limited entity of unknown etiology. It generally affects the cervical lymph nodes, and its symptoms are varied. The following is the case of a previously healthy 29-year-old man with generalized lymphadenopathy associated with significant unintended weight loss, intermittent high fever, nocturnal sweating, and general malaise. Fluorine-18-labeled deoxyglucose positron emission tomography (PET / CT 18F-FDG) revealed multiple nodes with intense metabolic activity suggestive of malignancy, infectious entities, or autoimmune diseases, which were ruled out. Histopathological diagnosis confirmed necrotizing histiocytic lymphadenitis, compatible with KFD, a rare and underdiagnosed disease, where early recognition could avoid unnecessary diagnostic or therapeutic interventions.